Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology.

PubWeight™: 0.81‹?›

🔗 View Article (PMID 27143508)

Published in Sci Rep on May 04, 2016

Authors

Li Gao1, Xiao-Dong Wang2,3, Yang-Yang Niu2,3, Dan-Dan Duan1,4, Xue Yang2,3, Jian Hao2,3, Cui-Hong Zhu2,3, Dan Chen5, Ke-Xin Wang1,4, Xue-Mei Qin1, Xiong-Zhi Wu3,6

Author Affiliations

1: Modern Research Center for Traditional Chinese Medicine, Shanxi University, Taiyuan 030006, PR China.
2: Tianjin Medical University, Tianjin, 300070, China.
3: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
4: College of Chemistry and Chemical Engineering, Shanxi University, Taiyuan 030006, PR China.
5: Department of Pharmacology, Basic Medical College, Tianjin Medical University, Tianjin, 300070, China.
6: Tianjin People's Hospital, NO.190 Jieyuan Road, Hongqiao, District, 300000, China.

Articles cited by this

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

AKT/PKB signaling: navigating downstream. Cell (2007) 31.26

Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics (2010) 26.76

Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol (2008) 8.51

Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer (1985) 7.67

Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions. Lancet (2012) 4.76

Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin (2012) 4.13

Multicomponent therapeutics for networked systems. Nat Rev Drug Discov (2005) 3.99

Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov (2009) 3.20

A network view of disease and compound screening. Nat Rev Drug Discov (2009) 2.90

Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol (2005) 2.87

Analyzing biological network parameters with CentiScaPe. Bioinformatics (2009) 1.91

Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin (2015) 1.55

Cancer therapy reform. Science (2010) 1.54

HIT: linking herbal active ingredients to targets. Nucleic Acids Res (2010) 1.50

Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol (2005) 1.41

TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis. Nucleic Acids Res (2012) 1.39

Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med (2013) 1.39

FoxD3-regulated microRNA-137 suppresses tumour growth and metastasis in human hepatocellular carcinoma by targeting AKT2. Oncotarget (2014) 1.22

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer (2007) 1.19

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform (2014) 1.19

An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. J Cancer Res Ther (2012) 1.18

Akt2 expression correlates with prognosis of human hepatocellular carcinoma. Oncol Rep (2004) 1.12

OncoDB.HCC: an integrated oncogenomic database of hepatocellular carcinoma revealed aberrant cancer target genes and loci. Nucleic Acids Res (2006) 1.06

Zinc fingers and homeoboxes 2 inhibits hepatocellular carcinoma cell proliferation and represses expression of Cyclins A and E. Gastroenterology (2012) 1.00

ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method. Bioinformatics (2013) 0.99

Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer: a population-based study. Cancer (2014) 0.99

Combination chemotherapy with capecitabine and cisplatin for patients with metastatic hepatocellular carcinoma. Ann Oncol (2009) 0.99

The use of complementary and alternative medicine by cancer patients undergoing radiation therapy. Am J Clin Oncol (2006) 0.95

Liverome: a curated database of liver cancer-related gene signatures with self-contained context information. BMC Genomics (2011) 0.95

A systems biology-based investigation into the therapeutic effects of Gansui Banxia Tang on reversing the imbalanced network of hepatocellular carcinoma. Sci Rep (2014) 0.94

Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw (2014) 0.93

Pilot study of combination chemotherapy of S-1, a novel oral DPD inhibitor, and interferon-alpha for advanced hepatocellular carcinoma with extrahepatic metastasis. Cancer (2008) 0.91

Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer (2013) 0.90

Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy. Integr Cancer Ther (2010) 0.89

Men with cancer: is their use of complementary and alternative medicine a response to needs unmet by conventional care? Eur J Cancer Care (Engl) (2007) 0.88

Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology (2008) 0.88

Autophagy induced by baicalin involves downregulation of CD147 in SMMC-7721 cells in vitro. Oncol Rep (2011) 0.87

Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther (2012) 0.87

Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med (2014) 0.86

Gekko-sulfated glycopeptide inhibits tumor angiogenesis by targeting basic fibroblast growth factor. J Biol Chem (2012) 0.86

Hepatocellular carcinoma in Asia: Prevention strategy and planning. World J Hepatol (2015) 0.85

Epirubicin and etoposide combination chemotherapy to treat hepatocellular carcinoma patients: a phase II study. Eur J Cancer (1997) 0.85

Effects of β-sitosterol derived from Artemisia capillaris on the activated human hepatic stellate cells and dimethylnitrosamine-induced mouse liver fibrosis. BMC Complement Altern Med (2014) 0.84

Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget (2015) 0.83

Combination therapy of oral fluoropyrimidine anticancer drug S-1 and interferon alpha for HCC patients with extrahepatic metastases. Oncology (2008) 0.80